Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 143pembrolizumab 127Nivolumab 116Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 73Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Ipilimumab 55Docetaxel 54Bortezomib 54Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × IT-101 × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT02010567 2020-11-03

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Terminated
32 enrolled 18 charts
Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡